Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor

publication date: Feb 27, 2020

MapKure, a JV formed by Beijing's BeiGene and SpringWorks Therapeutics of Connecticut, has dosed the first patient in an Australian trial of BeiGene's second-gen B-RAF inhibitor. BGB-3245 is aimed at patients with advanced or refractory solid tumors that have B-RAF mutations. SpringWorks was formed in 2017 as a spin-out from Pfizer with two Pfizer targeted small-molecule oncology drugs. MapKure is also starting a Phase I trial in the US of BGB-3245, which will be an expansion of the Australian trial. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 06160) (NYSE: PFE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital